|Dr. Joachim Kreuzburg||Chairman & CEO||891k||N/A||1965|
|Mr. Heiko Imöhl||VP of Group Financing & Investor Relations||N/A||N/A||N/A|
|Ms. Petra Kirchhoff||Head of Corp. Communications & IR||N/A||N/A||1969|
|Mr. John Gerard Mackay||Exec. VP of Marketing, Sales & Services for Lab Products and Services Division||N/A||N/A||1962|
|Benedikt Orzelek||Head of Investor Relations||N/A||N/A||N/A|
|Olivier Guitard||Head of Controlling BPS||N/A||N/A||N/A|
Sartorius Stedim Biotech S.A. produces and sells instruments and consumables for the biopharmaceutical industry worldwide. The company offers various products, such as cell lines; cell culture media; bioreactors; and a range of products for separation, purification, and concentration processes, as well as products and systems for storage and transportation of intermediate and finished biological products. It also provides cell cultivation, fermentation, filtration, purification, and fluid management services; single-use and reusable hollow-fiber membrane devices, as well as presterilized assemblies for cell and gene therapy applications; and cell harvesting and various other solutions for intensified bioprocesses. In addition, the company offers data analytics software for modeling and optimizing processes of biopharmaceutical development and production. It serves manufacturers of pharmaceuticals, foods, and chemicals, as well as research and development laboratories. The company was founded in 1870 and is headquartered in Aubagne, France. Sartorius Stedim Biotech S.A. is a subsidiary of Sartorius AG.
Sartorius Stedim Biotech S.A.’s ISS governance QualityScore as of 1 February 2023 is 9. The pillar scores are Audit: 6; Board: 8; Shareholder rights: 9; Compensation: 10.